Emergent BioSolutions Inc. to Post FY2022 Earnings of $1.31 Per Share, Cantor Fitzgerald Forecasts (NYSE:EBS)

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) – Equities research analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for shares of Emergent BioSolutions in a research note issued on Monday, May 2nd. Cantor Fitzgerald analyst B. Folkes now anticipates that the biopharmaceutical company will earn $1.31 per share for the year, down from their previous forecast of $2.00. Cantor Fitzgerald has a “Neutral” rating on the stock.

Emergent BioSolutions (NYSE:EBS – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.05). The business had revenue of $307.50 million for the quarter, compared to analysts’ expectations of $282.54 million. Emergent BioSolutions had a return on equity of 16.05% and a net margin of 8.96%. The business’s revenue for the quarter was down 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.53 earnings per share.

Several other equities analysts have also issued reports on EBS. Cowen decreased their target price on Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Benchmark raised Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research report on Thursday, January 20th. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Friday, April 29th. Zacks Investment Research upgraded Emergent BioSolutions from a “strong sell” rating to a “hold” rating and set a $45.00 price objective on the stock in a report on Friday, February 18th. Finally, Wells Fargo & Company dropped their price objective on Emergent BioSolutions from $46.00 to $38.00 in a report on Wednesday. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Emergent BioSolutions currently has an average rating of “Hold” and an average price target of $48.57.

EBS opened at $33.37 on Wednesday. The stock’s 50-day moving average price is $40.56 and its 200 day moving average price is $43.25. Emergent BioSolutions has a 12-month low of $29.88 and a 12-month high of $68.03. The company has a current ratio of 4.42, a quick ratio of 2.81 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of 11.47 and a beta of 0.98.

Hedge funds have recently made changes to their positions in the business. Eaton Vance Management lifted its holdings in shares of Emergent BioSolutions by 39.8% in the 4th quarter. Eaton Vance Management now owns 2,745 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 782 shares during the period. Cutler Group LP grew its position in shares of Emergent BioSolutions by 250.0% in the first quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 500 shares during the period. Covestor Ltd purchased a new stake in shares of Emergent BioSolutions in the fourth quarter valued at $49,000. Schroder Investment Management Group purchased a new stake in shares of Emergent BioSolutions in the fourth quarter valued at $54,000. Finally, First Bank & Trust grew its position in shares of Emergent BioSolutions by 32.3% in the fourth quarter. First Bank & Trust now owns 1,850 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 452 shares during the period. Institutional investors own 86.02% of the company’s stock.

About Emergent BioSolutions (Get Rating)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Featured Stories